{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:55:30Z","timestamp":1793105730361,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04483-3","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:16:55Z","timestamp":1767025015000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cross-speciality collaborative care in complex immune-mediated inflammatory diseases: treating the person living with the condition"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8283-6519","authenticated-orcid":false,"given":"Laura","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5981-3984","authenticated-orcid":false,"given":"Christine","family":"Bundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Langmead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanchan","family":"Bhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6849-6830","authenticated-orcid":false,"given":"Mark","family":"Sephton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4176-2549","authenticated-orcid":false,"given":"Liesbet","family":"Van Rossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"4483_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/biology11070973","author":"MA Ortega","year":"2022","unstructured":"Ortega MA, Garc\u00eda-Montero C, Fraile-Martinez O, Alvarez-Mon MA, G\u00f3mez-Lahoz AM, Lahera G, et al. Immune-mediated diseases from the point of view of psychoneuroimmunoendocrinology. Biology. 2022. https:\/\/doi.org\/10.3390\/biology11070973.","journal-title":"Biology"},{"issue":"7","key":"4483_CR2","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1007\/s12325-019-00964-z","volume":"36","author":"D Aletaha","year":"2019","unstructured":"Aletaha D, Epstein AJ, Skup M, Zueger P, Garg V, Panaccione R. Risk of developing additional immune-mediated manifestations: a retrospective matched cohort study. Adv Ther. 2019;36(7):1672\u201383.","journal-title":"Adv Ther"},{"key":"4483_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2023.100204","volume":"7","author":"JM Anaya","year":"2023","unstructured":"Anaya JM, Beltr\u00e1n S. The autoimmune tautology revisited. J Transl Autoimmun. 2023;7:100204.","journal-title":"J Transl Autoimmun"},{"issue":"7","key":"4483_CR4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1056\/NEJMra1909094","volume":"385","author":"G Schett","year":"2021","unstructured":"Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med. 2021;385(7):628\u201339.","journal-title":"N Engl J Med"},{"issue":"10","key":"4483_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103410","volume":"22","author":"G Monteleone","year":"2023","unstructured":"Monteleone G, Moscardelli A, Colella A, Marafini I, Salvatori S. Immune-mediated inflammatory diseases: common and different pathogenic and clinical features. Autoimmun Rev. 2023;22(10):103410.","journal-title":"Autoimmun Rev"},{"issue":"978","key":"4483_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","volume":"83","author":"A Kuek","year":"2007","unstructured":"Kuek A, Hazleman BL, Ost\u00f6r AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251\u201360.","journal-title":"Postgrad Med J"},{"key":"4483_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae109","author":"R de Francisco","year":"2024","unstructured":"de Francisco R, P\u00e9rez-Mart\u00ednez I, Casta\u00f1o-Garc\u00eda A, Carballo-Folgoso L, Fl\u00f3rez-D\u00edez P, Garc\u00eda-P\u00e9rez C, et al. Do patients with inflammatory bowel disease really know what other immune-mediated inflammatory diseases they are diagnosed with? J Crohns Colitis. 2024. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae109.","journal-title":"J Crohns Colitis"},{"issue":"7","key":"4483_CR8","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/ard.2007.075754","volume":"67","author":"N Zeboulon","year":"2008","unstructured":"Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008;67(7):955\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4483_CR9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s41584-024-01181-x","volume":"20","author":"SLN Clarke","year":"2024","unstructured":"Clarke SLN, Maghsoudlou P, Guly CM, Dick AD, Ramanan AV. The management of adult and paediatric uveitis for rheumatologists. Nat Rev Rheumatol. 2024;20(12):795\u2013808.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"4483_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/heartjnl-2019-316378","volume":"108","author":"R Agca","year":"2022","unstructured":"Agca R, Smulders Y, Nurmohamed M. Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice. Heart. 2022;108(1):73\u20139.","journal-title":"Heart"},{"key":"4483_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3899\/jrheum.091461","volume":"85","author":"H El-Gabalawy","year":"2010","unstructured":"El-Gabalawy H, Guenther LC, Bernstein CN. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl. 2010;85:2\u201310.","journal-title":"J Rheumatol Suppl"},{"key":"4483_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.phrs.2018.01.009","volume":"133","author":"G Medina","year":"2018","unstructured":"Medina G, Vera-Lastra O, Peralta-Amaro AL, Jim\u00e9nez-Arellano MP, Saavedra MA, Cruz-Dom\u00ednguez MP, et al. Metabolic syndrome, autoimmunity and rheumatic diseases. Pharmacol Res. 2018;133:277\u201388.","journal-title":"Pharmacol Res"},{"key":"4483_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jpsychores.2017.07.015","volume":"101","author":"RA Marrie","year":"2017","unstructured":"Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, et al. Increased incidence of psychiatric disorders in immune-mediated inflammatory disease. J Psychosom Res. 2017;101:17\u201323.","journal-title":"J Psychosom Res"},{"key":"4483_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108392","volume":"214","author":"J Spierings","year":"2020","unstructured":"Spierings J, Sloeserwij A, Vianen ME, de Boer JH, Sigurdsson V, van de Wijgert J, et al. Health-related quality of life in patients with immune mediated inflammatory diseases: a cross-sectional, multidisciplinary study. Clin Immunol. 2020;214:108392.","journal-title":"Clin Immunol"},{"key":"4483_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13041019","author":"M Vernero","year":"2024","unstructured":"Vernero M, Saibeni S, Scalvini D, Cicalini C, Chiarello L, Nardi S, et al. Prevalence and clinical impact of immune-mediated inflammatory diseases in patients with inflammatory bowel disease: results from a large retrospective observational study. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13041019.","journal-title":"J Clin Med"},{"issue":"4","key":"4483_CR16","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s40123-024-00895-1","volume":"13","author":"F Sha","year":"2024","unstructured":"Sha F, Li H, Zhang L, Liang F. Evidence for genetic causal relationships between multiple immune-mediated inflammatory diseases and age-related macular degeneration: a univariable and multivariable mendelian randomization study. Ophthalmol Ther. 2024;13(4):955\u201367.","journal-title":"Ophthalmol Ther"},{"issue":"6","key":"4483_CR17","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/apt.13940","volume":"45","author":"G Conway","year":"2017","unstructured":"Conway G, Velonias G, Andrews E, Garber JJ, Yajnik V, Ananthakrishnan AN. The impact of co-existing immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45(6):814\u201323.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"4483_CR18","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/bjd.18296","volume":"182","author":"L Andersen","year":"2020","unstructured":"Andersen L, Nyeland ME, Nyberg F. Increasing severity of atopic dermatitis is associated with a negative impact on work productivity among adults with atopic dermatitis in France, Germany, the U.K. and the U.S.A. Br J Dermatol. 2020;182(4):1007\u201316.","journal-title":"Br J Dermatol"},{"key":"4483_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/23743735221125439","volume":"9","author":"S Marzban","year":"2022","unstructured":"Marzban S, Najafi M, Agolli A, Ashrafi E. Impact of patient engagement on healthcare quality: a scoping review. J Patient Exp. 2022;9:23743735221125439.","journal-title":"J Patient Exp"},{"issue":"1","key":"4483_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4483_CR21","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706\u201319.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4483_CR22","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1093\/rheumatology\/keac260","volume":"61","author":"L Tucker","year":"2022","unstructured":"Tucker L, Allen A, Chandler D, Ciurtin C, Dick A, Foulkes A, et al. Executive summary: the 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. Rheumatology. 2022;61(9):3514\u201320.","journal-title":"Rheumatology"},{"issue":"10","key":"4483_CR23","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599\u2013613.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"4483_CR24","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924\u201339.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"4483_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5\u201332.","journal-title":"Arthritis Rheumatol"},{"key":"4483_CR26","unstructured":"National Institute for Health and Care Excellence: Adalimumab and dexamethasone for treating non-infectious uveitis. Available at www.nice.org.uk\/guidance\/ta460 In.; 2017."},{"issue":"1","key":"4483_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02746-5","volume":"21","author":"PC Taylor","year":"2023","unstructured":"Taylor PC, Askari A, Choy E, Ehrenstein MR, Else S, Nisar MK. Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease. BMC Med. 2023;21(1):55.","journal-title":"BMC Med"},{"issue":"1","key":"4483_CR28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198\u2013206.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"4483_CR29","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41577-021-00603-1","volume":"21","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Gravallese EM. Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol. 2021;21(10):680\u20136.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"4483_CR30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s12325-018-0672-6","volume":"35","author":"F Rizzello","year":"2018","unstructured":"Rizzello F, Olivieri I, Armuzzi A, Ayala F, Bettoli V, Bianchi L, et al. Multidisciplinary management of spondyloarthritis-related immune-mediated inflammatory disease. Adv Ther. 2018;35(4):545\u201362.","journal-title":"Adv Ther"},{"issue":"12","key":"4483_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11926-018-0785-6","volume":"20","author":"R Haberman","year":"2018","unstructured":"Haberman R, Perez-Chada LM, Merola JF, Scher J, Ogdie A, Reddy SM. Bridging the gaps in the care of psoriasis and psoriatic arthritis: the role of combined clinics. Curr Rheumatol Rep. 2018;20(12):76.","journal-title":"Curr Rheumatol Rep"},{"key":"4483_CR32","doi-asserted-by":"crossref","unstructured":"de Silva S, Steed H, Allen PB, Vegad C, Crooks J, Jaulim A, Hart A: Assessing disease control in inflammatory bowel disease: a real world cross-sectional study in the UK (PODCAST-IBD). Curr Med Res Opin.\u00a02024;40(11):1847\u201354.","DOI":"10.1080\/03007995.2024.2410928"},{"issue":"1","key":"4483_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12348-020-00202-6","volume":"10","author":"F Nicolela Susanna","year":"2020","unstructured":"Nicolela Susanna F, Pavesio C. A review of ocular adverse events of biological anti-TNF drugs. J Ophthalmic Inflamm Infect. 2020;10(1):11.","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"4","key":"4483_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041871","volume":"11","author":"KF Hjuler","year":"2021","unstructured":"Hjuler KF, Dige A, Agnholt J, Laurberg TB, Loft AG, M\u00f8ller LF, et al. Effectiveness of interdisciplinary combined dermatology-gastroenterology-rheumatology clinical care compared to usual care in patients with immune-mediated inflammatory diseases: a parallel group, non-blinded, pragmatic randomised trial. BMJ Open. 2021;11(4):e041871.","journal-title":"BMJ Open"},{"issue":"1","key":"4483_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-017-0706-0","volume":"20","author":"T Soleymani","year":"2017","unstructured":"Soleymani T, Reddy SM, Cohen JM, Neimann AL. Early recognition and treatment heralds optimal outcomes: the benefits of combined rheumatology-dermatology clinics and integrative care of psoriasis and psoriatic arthritis patients. Curr Rheumatol Rep. 2017;20(1):1.","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"4483_CR36","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s10067-020-05391-y","volume":"40","author":"D Sumpton","year":"2021","unstructured":"Sumpton D, Hannan E, Kelly A, Tunnicliffe D, Ming A, Hassett G, et al. Clinicians\u2019 perspectives of shared care of psoriatic arthritis and psoriasis between rheumatology and dermatology: an interview study. Clin Rheumatol. 2021;40(4):1369\u201380.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"4483_CR37","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s10067-018-4238-4","volume":"37","author":"MM Luchetti","year":"2018","unstructured":"Luchetti MM, Benfaremo D, Campanati A, Molinelli E, Ciferri M, Cataldi S, et al. Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic. Clin Rheumatol. 2018;37(10):2741\u20139.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"4483_CR38","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00296-022-05126-z","volume":"42","author":"K Klavdianou","year":"2022","unstructured":"Klavdianou K, Stavropoulou M, Panagakis P, Papoutsaki M, Panagiotopoulos A, Koutsianas C, et al. Patient characteristics, treatment patterns and disease outcomes in patients with psoriatic arthritis followed in a combined dermatology-rheumatology clinic: a retrospective real-world study. Rheumatol Int. 2022;42(6):1035\u201341.","journal-title":"Rheumatol Int"},{"issue":"2","key":"4483_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5334\/ijic.7741","volume":"25","author":"E Chamorro-de-Vega","year":"2025","unstructured":"Chamorro-de-Vega E, Gonz\u00e1lez CM, Mench\u00e9n L, Baniandr\u00e9s O, Herranz A, Lobo-Rodr\u00edguez C, et al. New model of integrated care for patients with immune-mediated inflammatory diseases. Int J Integr Care. 2025;25(2):19.","journal-title":"Int J Integr Care"},{"key":"4483_CR40","doi-asserted-by":"publisher","first-page":"175628482513235","DOI":"10.1177\/17562848251323529","volume":"18","author":"OM Nardone","year":"2025","unstructured":"Nardone OM, Calabrese G, La Mantia A, Villani GD, Megna M, Cacciapuoti S, et al. Reducing diagnostic delays of extraintestinal manifestations in inflammatory bowel disease: a comparative study of a multidisciplinary outpatient clinic versus conventional referral specialists. Therap Adv Gastroenterol. 2025;18:17562848251323528.","journal-title":"Therap Adv Gastroenterol"},{"issue":"3","key":"4483_CR41","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/jvc2.169","volume":"2","author":"L Savage","year":"2023","unstructured":"Savage L, Kaul A, Gorecki P. Collaboration in the management of psoriasis and psoriatic arthritis: a survey of joint working in UK clinical practice. JEADV Clin Pract. 2023;2(3):559\u201365.","journal-title":"JEADV Clin Pract"},{"key":"4483_CR42","doi-asserted-by":"crossref","unstructured":"Hjuler KF, M\u00f8ller LF, Elgaard CDB, Ga\u00efni L, Iversen L, Hjuler TF: On the interdisciplinary treatment and management of patients with immune-mediated inflammatory diseases. A study on patients\u2019 personal experiences and perspectives. J Multidiscip Healthc. 2024, 17:2635\u20132646.","DOI":"10.2147\/JMDH.S432820"},{"issue":"Suppl 3","key":"4483_CR43","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-3-s15","volume":"17","author":"I Barker","year":"2017","unstructured":"Barker I, Steventon A, Deeny S. Patient activation is associated with fewer visits to both general practice and emergency departments: a cross-sectional study of patients with long-term conditions. Clin Med. 2017;17(Suppl 3):s15.","journal-title":"Clin Med"},{"issue":"2","key":"4483_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.reuma.2016.03.005","volume":"13","author":"R Queiro","year":"2017","unstructured":"Queiro R, Coto P, Rodr\u00edguez J, Notario J, Nav\u00edo Marco T, de la Cueva P, et al. Multidisciplinary care models for patients with psoriatic arthritis. Reumatol Clin. 2017;13(2):85\u201390.","journal-title":"Reumatol Clin"},{"issue":"1","key":"4483_CR45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.apmr.2015.09.022","volume":"97","author":"C Feldthusen","year":"2016","unstructured":"Feldthusen C, Dean E, Forsblad-d\u2019Elia H, Mannerkorpi K. Effects of person-centered physical therapy on fatigue-related variables in persons with rheumatoid arthritis: a randomized controlled trial. Arch Phys Med Rehabil. 2016;97(1):26\u201336.","journal-title":"Arch Phys Med Rehabil"},{"issue":"2","key":"4483_CR46","doi-asserted-by":"publisher","first-page":"128","DOI":"10.7861\/futurehosp.3-2-128","volume":"3","author":"S Eaton","year":"2016","unstructured":"Eaton S. Delivering person-centred care in long-term conditions. Future Hosp J. 2016;3(2):128\u201331.","journal-title":"Future Hosp J"},{"issue":"1","key":"4483_CR47","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/rheumatology\/keaa598","volume":"60","author":"CY Vandevelde","year":"2020","unstructured":"Vandevelde CY, Harnden K, Freeston J, Barr A, Selinger CP, Shams K, et al. Improving patient care through a collaborative effort in the Leeds Combined Psoriatic Service: an effective provision of multi-specialty input. Rheumatology. 2020;60(1):467\u201370.","journal-title":"Rheumatology"},{"issue":"Suppl 1","key":"4483_CR48","first-page":"A94","volume":"73","author":"A Hussain","year":"2024","unstructured":"Hussain A, Ally Speight R, Reynolds NJ, Havelin A, Ball S, Lamb CA. P75 \u2018IBD-Dermatology\u2019: a novel and collaborative working model. Gut. 2024;73(Suppl 1):A94\u2013A94.","journal-title":"Gut"},{"key":"4483_CR49","unstructured":"National Institute for Health and Care Excellence. Spondyloarthritis in over 16s: diagnosis and management NICE guideline NG65. London: National Institute for Health and Care Excellence, 2017."},{"key":"4483_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae172","author":"LC Coates","year":"2024","unstructured":"Coates LC, Bukhari M, Chan A, Choy E, Galloway J, Gullick N, et al. Enhancing current guidance for psoriatic arthritis and its comorbidities: recommendations from an expert consensus panel. Rheumatology (Oxford). 2024. https:\/\/doi.org\/10.1093\/rheumatology\/keae172.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"4483_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jmir.2017.02.071","volume":"48","author":"L Morley","year":"2017","unstructured":"Morley L, Cashell A. Collaboration in health care. J Med Imaging Radiat Sci. 2017;48(2):207\u201316.","journal-title":"J Med Imaging Radiat Sci"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04483-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04483-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04483-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T17:01:53Z","timestamp":1767027713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-025-04483-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4483"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04483-3","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We did not consider the patient feedback workshops to be research. These were designed to give patient and staff an opportunity to feedback about the current service. There were no fixed protocols or criteria. As such (and in line with the NHS research services guidance, which can be found at\n                      \n                      ), we did not need to seek ethics approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PCT: Grants\/research support from Alfasigma and payments made to the University of Oxford; consulting fees from AlfaSigma, AbbVie, ACELYRIN, INC., Biogen, Fresenius, Gilead Sciences, Inc., Roche; Takeda; Eli Lilly; Nordic Pharma; Pfizer; and UCB; safety monitoring board participation for Immunovant, Moonlake, and Sanofi. LS: Funding support for education, advisory board participation and\/or received research funding from AbbVie, Almirall, Amgen, Aspire Pharma, Biogen, Boehringer-Ingelheim, Bristol-Myers-Squibb, Celgene, Celltrion, Fresenius Kabi, Galderma, Janssen, Leo, Lilly, Medac, Moonlake, Novartis, Pfizer, Sanofi, Takeda, UCB. CB: Research grant support from Amgen and Beiersdorf, consultancy for Abbvie and Beiersdorf. Honoraria received from Abbvie, Almirall, Galapagos, Novartis, Pfizer and UCB. LL: Funding support for education from Takeda. KB: Paid speaker for AbbVie, Jansen and Novartis. MS and LVR are employees of AbbVie and may hold AbbVie stock.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"693"}}